TUXUMDON SARATONIDA CA-125 VA HE4 MARKERLARINING DIAGNOSTIK SAMARADORLIGINI BAHOLASH
DOI:
https://doi.org/10.5281/zenodo.23553303Keywords:
tuxumdon saratoni, CA-125, HE4, ROMA, diagnostik sezgirlik, spetsifiklik, adneksal massaAbstract
Maqsad — tuxumdonlarning epitelial xavfli o‘smalarini aniqlashda CA-125 va HE4 onkomarkerlarining sezgirligi, spetsifikligi va klinik qo‘llash chegaralarini taqqoslash. Material va usullar: 2024-yilgi O‘zbekiston milliy klinik protokoli, xalqaro konsensus, diagnostik aniqlikka oid meta-tahlillar va ko‘p markazli tadqiqotlar asosida narrativ-tahliliy sharh o‘tkazildi. Natijalar: klinik kontekst va chegara qiymatlariga qarab, HE4 ko‘pincha yuqoriroq spetsifiklikni namoyon etadi; ayrim meta-tahlillarda ROMA algoritmi yuqori diagnostik diskriminatsiya (farqlash qobiliyati) ko‘rsatkichlarga erishgan, biroq xalqaro konsensus ultratovushga asoslangan modellarning ustunligini ta’kidlaydi. Xulosa: CA-125 va HE4 natijalari transvaginal ultratovush tekshiruvi (UTT), menopauza holati, buyrak funksiyasi va klinik xavf bilan birgalikda talqin qilinishi zarur.References
1. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Tuxumdonlar saratoni nozologiyasi bo‘yicha milliy klinik protokol (401-son buyruqqa ilova). https://api-portal.gov.uz/uploads/10/2025/05/14/093fc9c8-07cc-8b86-09b6-fccbafb50450_media_.pdf
2. American College of Obstetricians and Gynecologists. (2016). Evaluation and management of adnexal masses (Practice Bulletin No. 174; reaffirmed 2025). https://www.acog.org/clinical/clinical-guidance/ practice-bulletin/articles/2016/11/evaluation-and-management-of-adnexal-masses
3. Timmerman, D., Planchamp, F., Bourne, T., et al. (2021). ESGO/ISUOG/IOTA/ESGE consensus statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics & Gynecology, 58(1), 148–168.
4. Wang, J., Gao, J., Yao, H., Wu, Z., Wang, M., & Qi, J. (2014). Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: A meta-analysis. Tumor Biology, 35, 6127–6138. https://doi. org/10.1007/s13277-014-1811-6
5. Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis. (2014). Oncology Letters. https://pmc.ncbi.nlm.nih.gov/articles/PMC4051564/
6. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: A systematic review and meta-analysis. (2021). Acta Obstetricia et Gynecologica Scandinavica. https://pubmed.ncbi.nlm.nih.gov/34212386/
7. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: A meta-analysis. (2016). International Journal of Gynecological Cancer. https://pubmed. ncbi.nlm.nih.gov/27540691/
8. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. (2016). Gynecologic Oncology. https://doi. org/10.1016/j.ygyno.2016.01.016
9. American College of Obstetricians and Gynecologists. (2017). The role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer in women at average risk. https://www.acog.org/clinical/ clinical-guidance/committee-opinion/articles/2017/09/the-role-of-the-obstetriciangynecologist-in-the-earlydetection-of-epithelial-ovarian-cancer-in-women-at-average-risk
10. Diagnostic measures comparison for ovarian malignancy risk in epithelial ovarian cancer patients: A metaanalysis. (2021). https://pubmed.ncbi.nlm.nih.gov/34453074/
11. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: A meta-analysis. (2012). https://pubmed.ncbi.nlm.nih.gov/22712526/
12. O‘zbekiston Respublikasi Sog‘liqni saqlash vazirligi. (2024). Milliy klinik protokollarni ishlab chiqish va amaliyotga tatbiq etish haqida ma’lumot. https://gov.uz/uz/ssv/news/view/15350
Downloads
Published
How to Cite
Issue
Section
